X

Xiamen Amoytop Biotech Co Ltd
SSE:688278

Watchlist Manager
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Watchlist
Price: 71.69 CNY -3.54% Market Closed
Market Cap: 29.2B CNY
Have any thoughts about
Xiamen Amoytop Biotech Co Ltd?
Write Note

Xiamen Amoytop Biotech Co Ltd
Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Xiamen Amoytop Biotech Co Ltd
Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash CAGR 3Y CAGR 5Y CAGR 10Y
X
Xiamen Amoytop Biotech Co Ltd
SSE:688278
Cash
ÂĄ413m
CAGR 3-Years
1 504%
CAGR 5-Years
429%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Cash
ÂĄ15B
CAGR 3-Years
33%
CAGR 5-Years
32%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Cash
ÂĄ3.8B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Cash
ÂĄ1.9B
CAGR 3-Years
-1%
CAGR 5-Years
263%
CAGR 10-Years
91%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Cash
ÂĄ5.6B
CAGR 3-Years
3%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Imeik Technology Development Co Ltd
SZSE:300896
Cash
ÂĄ2.4B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Xiamen Amoytop Biotech Co Ltd
Glance View

Market Cap
29.2B CNY
Industry
Biotechnology

Xiamen Amoytop Biotech Co. Ltd. engages in the research and development of genetic engineering technology. The company is headquartered in Xiamen, Fujian and currently employs 1,261 full-time employees. The company went IPO on 2020-01-17. The firm's main research and development direction is immune-related cytokine drugs, focusing on systemic immune solutions based on cytokine drugs, and its products mainly include Peginterferon alfa-2b Injection, rhGM-CSF (Recombinant Human Granulocyte/Macrophage Colony-Stimulating Factor for Injection), rHuG-CSF (Recombinant Human Granulocyte-Colony Stimulating Factor for Injection) and Recombinant Human Interleukin-11 for Injection. The firm distributes its products within domestic market and to overseas markets.

Intrinsic Value
86.96 CNY
Undervaluation 18%
Intrinsic Value
Price
X

See Also

What is Xiamen Amoytop Biotech Co Ltd's Cash?
Cash
413m CNY

Based on the financial report for Dec 31, 2023, Xiamen Amoytop Biotech Co Ltd's Cash amounts to 413m CNY.

What is Xiamen Amoytop Biotech Co Ltd's Cash growth rate?
Cash CAGR 5Y
429%

Over the last year, the Cash growth was 37%. The average annual Cash growth rates for Xiamen Amoytop Biotech Co Ltd have been 1 504% over the past three years , 429% over the past five years .

Back to Top